Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 21;10:8477. doi: 10.1038/s41598-020-65414-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

FICZ-induced MMP1 expression is blocked by CH-223191 and AHR ligand-induced AHR protein degradation is blocked by CH-223191 and proteasome inhibitor MG132. (a) GOFs were plated and treated with vehicle or CH-223191 (at 1 or 10 μM) for 1 hour before treatment with vehicle or 1 μM FICZ for an additional 24 or 72 hours. CH-223191 was added every 24 hours in the 72-hour samples. Cell lysates were collected and analyzed by Western blotting for MMP1 and β-tubulin (loading control) (b). Cells treated as in (a) were analyzed for AHR and β-tubulin (loading control) by Western blot. (c) GOFs were plated and treated with vehicle or proteasome inhibitor MG132 (at 10 or 25 μM) for 1 hour before treatment with vehicle or 1 μM FICZ for an additional 24 or 72 hours. MG132 was added every 24 hours in the 72-hour samples. Cell lysates were collected and analyzed by Western blotting for AHR and β-tubulin (loading control). Full length blots are shown in Supplemental Fig. 19).